Evidence map›Paper›PMID 27261480›Full record

ArticleCancer discovery2016

Senescence Can Be BETter without the SASP?

Maria Grazia Vizioli, Peter D Adams

Open access · greenAbstract readComment
In one paragraph

Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Maria Grazia VizioliBeatson Institute for Cancer Research, Bearsden, Glasgow, United Kingdom. Institute of Cancer Sciences College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Peter D AdamsBeatson Institute for Cancer Research, Bearsden, Glasgow, United Kingdom. Institute of Cancer Sciences College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. p.adams@beaston.gla.ac.uk.
Cancer Research UK Scotland Institute · GB

Funding

STRUCTURAL BASIS FOR EPIGENETICS IN AGING AND LONGEVITYP01AG031862 · NIA · WISTAR INSTITUTE · PI GARCIA, BENJAMIN A · 2008 to 2022
$28.3M
Cancer Research UK 16566NIA NIH HHS P01 AG031862
6 · The paper itself

Abstract

Global remodeling of the chromatin landscape occurs during senescence, although its functional consequence is still unclear. In this issue, Tasdemir and colleagues show that the epigenetic regulator BRD4 is required for expression of the proinflammatory senescence-associated secretory phenotype and immune clearance of senescent cells in vitro and in vivo Their results could be useful in the design of novel therapies to treat aging-related diseases, including cancer.Cancer Discov; 6(6); 576-8. ©2016 AACR.See related article by Tasdemir et al., p. 612.

Indexed as

PhenotypeCellular SenescenceChromatinHumansChromatin

Identifiers

PMID27261480
PMCPMC6489500
OpenAlexW2408863319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.